Moderna said on Tuesday that its Covid-19 vaccine was “highly effective” for teens ages 12 to 17, according to results from a full clinical trial. The American company plans to apply for a permit to use its vaccine for this age group “early June” with “regulators around the world.”
If approved by health authorities, it will join the Pfizer-BioNTech vaccine, already authorized for adolescents in many countries, including the United States.
“We are encouraged that (the vaccine) has been shown to be very effective in preventing Covid-19 in adolescents.”The company’s president, Stefan Bansel, said in a press release. “We will present these findings to the FDA (US Medicines Agency, Editor’s Note) and to regulators around the world in early June and seek permission.”
Moderna’s study involved more than 3,700 participants between the ages of 12 and 17 in the United States, two-thirds of whom received the vaccine, and one-third of them received a placebo. “After two doses, no case of Covid-19 was observed in the vaccinated group (…) against four cases in the placebo group, resulting in the vaccine being 100% effective 14 days after the second dose.”Moderna in her statement. After a single dose, an efficacy of 93% was noted.
The vaccine was ‘Generally well tolerated’ And the No security concerns identified yet.Moderna adds, explaining that the side effects observed are the same as in adults (pain at the injection site, fatigue, chills, etc.).